Clinical trial of novel prostaglandin F2alpha derivative against glaucoma

Clinical trial of novel prostaglandin F2alpha derivative against glaucoma - Clinical trial of novel prostaglandin F2alpha derivative against glaucoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001526

Enrollment

100

Registered

2008-11-26

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma

Interventions

Topical ocular hypotensive eye drops Topical ocular hypotensive eye drops

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Glaucoma or ocular hypertension

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
IOP reducing effect of eye drops against glaucomatous eyes.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026